The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
I agree we will not rise significantly until we get more detailed news from the BOD. This includes funding for P2/3, is Avion still funding this 100% out of the $25m previously promised. We will also need to see a more detailed time scale for the trial also. The last RNS, although placating fears by many of us, was far too light in detail.
I guess we will never get to know where the leak emanates and would hope it’s not within the company. As said, promising, but we need to have this resolved in a timely fashion.
https://www.mining.com/web/botswana-warns-of-dangers-in-dash-for-african-minerals/
Hope our ESG credentials aren’t questioned.
https://www.mining.com/web/africa-gears-up-to-keep-more-of-the-profits-from-lithium-boom/
ATM’s Lithium petalite concentrate should hopefully satisfy this requirement.
I think some people are taking out their frustration on NVS which is a tad unfair. He is not in control of the mining cadastre which it seems is the main cause of the JV not being signed. Frustrating yes, but you can’t lay the blame’s solely at one door.
AISC of $1248 is a lot better than many of us were thinking may be achieved. No doubt helped by better grades and the new contractor. Just wish DB had kept his eye on the ball a bit closer in the middle of last year. Onwards and upwards hopefully with Kouroussa getting closer to completion.
https://endpts.com/mercks-keytruda-nears-21b-in-sales-doubles-down-on-combo-trials/
Some info to take in.